Articles tagged "Antibodies"

2019 American Transplant Congress
Kidney Allograft Recipient Absence of Myeloperoxidase Decreases Donor-Specific Antibody Titers and Attenuates Antibody-Mediated Allograft Rejection
S. Miyairi, N. Dvorina, A. Valujuskikh, W. M. Baldwin 3rd, R. L. Fairchild
Immunology, Cleveland Clinic Lerner Institute, Cleveland, OH
*Purpose: The incidence of antibody-mediated kidney graft rejection continues to increase. We previously reported that dysregulated donor-specific antibody (DSA) responses were induced in B6.CCR5-/- mice…
2019 American Transplant Congress
Desensitization Using Only IVIG: Is That an Option for Highly-Sensitized Patients Waiting for Kidneys from Cadaveric Donors?
J. O. Paixão, L. R. Ulisses, P. S. Souza, G. Bezerra, F. Agena, H. P. Rodrgues, N. Panajotopoulos, F. J. Paula, E. David-Neto, M. R. Castro
Nefrologia, Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil
*Purpose: The reduction of anti-HLA has been proven to be efficient and safe in transplants of highly-sensitized with living donors (LD). The results of adopting…
2019 American Transplant Congress
Pre-emptive Ivig For Dsa Positive Living Donor Kidney Transplant Recipients
B. Abdalla¹, D. Kellner², A. Diaz², Y. Zheng³, E. Reed⁴, Q. J. Zhang⁴
¹Medicine, Division of Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, CA, ²David Geffen School of Medicine at UCLA, Los Angeles, CA, ³UCLA Immunogenetics Center, Los Angeles, CA, ⁴Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA
*Purpose: Intravenous immunoglobulin (IVIG) is used in desensitization regimens to modulate anti-human leukocyte antigen (HLA) donor-specific antibody (DSA) to facilitate transplantation of sensitized patients, however,…
2019 American Transplant Congress
Donor Derived Cell Free DNA Initiates De-Novo Donor Specific Antibody (DSA) Responses
S. Jordan¹, D. Sawinski², S. Dholakia³
¹Cedars-Sinai, Los Angeles, CA, ²Hospital of the University of Pennsylvania, Philadelphia, PA, ³CareDx, Brisbane, CA
*Purpose: We hypothesize that subclinical inflammation, resulting in molecular injury, may contribute to sensitization of the recipients’ immune system. Antigenic presentation of donor-derived nucleic acids,…
2019 American Transplant Congress
TACI Polymorphisms Associated with Increased Alloimmunity and Allograft Rejection
M. Garcia de Mattos-Barbosa¹, E. A. Farkash², J. L. Platt¹, M. Cascalho¹
¹Transplant Surgery, University of Michigan, Ann Arbor, MI, ²Pathology, University of Michigan, Ann Arbor, MI
*Purpose: Transmembrane activator and CAML interactor (TACI) controls B cell differentiation. The TACI gene is highly polymorphic (>95% of all genes) and frequently variants exhibit…
2019 American Transplant Congress
The Natural History and Time to Seroconversion of CMV in the Era of Post-Transplantation Chemoprophylaxis: A Single Center Study
S. Farran, T. Zangeneh, M. Al-Obaidi
Division of Infectious Diseases, University of Arizona, Tucson, AZ
*Purpose: The current cytomegalovirus (CMV) guidelines in solid organ transplantation recommend chemoprophylaxis (ppx) in post-kidney transplantation recipients. This approach has led to a reduction in…
2019 American Transplant Congress
Incidence of De Novo Donor Specific Antibodies and Treatment Response for AMR in Pediatric Kidney Transplant Recipients
S. Gattis¹, R. Liverman¹, A. Serluco¹, J. Yin¹, H. C. Sullivan², R. A. Bray³, H. M. Gebel³, S. Jernigan⁴, R. George⁴, P. D. Winterberg⁴, R. Garro⁴
¹Children's Healthcare of Atlanta, Atlanta, GA, ²Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, ³Emory University Hospital, Atlanta, GA, ⁴Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
*Purpose: Antibody-mediated rejection (AMR) is a significant complication in renal transplant patients. The aim of this study was to evaluate the incidence of de novo…
2019 American Transplant Congress
Angiotensin II Type 1 Receptor Antibodies Improve Risk Stratification for Kidney Allograft Outcomes at the Time of Transplantation
C. Lefaucheur¹, D. Viglietti¹, Y. Bouatou¹, A. Philippe², D. Pievani¹, O. Aubert¹, D. Glotz¹, C. Legendre¹, A. Loupy¹, D. Dragun²
¹Paris Translational Research Center for Organ Transplantation, Paris, France, ²Medical Faculty of the Charité Berlin, Berlin, Germany
*Purpose: Current state-of-the-art pre-transplant risk stratification relies on the HLA system. Non-HLA agonistic angiotensin II type 1 receptor antibodies (AT1R-Ab) have been associated with allograft…
2019 American Transplant Congress
CD19⁺Tim-1⁺ Regulatory B Cells Mediate the Balance of Th17 Treg to Decrease the Level of Donor-Specific Antibodies in Mice Secondary Skin Transplantation Model
Z. Wang, S. Fei, H. Chen, L. Sun, Z. Han, J. Tao, X. Ju, R. Tan, M. Gu
No.300 Guangzhou Road of Nanjing, Nanjing, China
*Purpose: In this study, we were aimed to explore the potential influence of CD19+Tim-1+ Regulatory B cells (Bregs) on the production of DSAs in a…
2019 American Transplant Congress
High HLA-DQ Epitope Mismatch Load and Low Tacrolimus Level Are Associated with Development of De Novo Donor Specific Antibody
D. Lee¹, B. Kim², J. Kim³, I. Kim⁴, M. Jeon⁵, J. Ahn¹, S. Choi⁶
¹Nephrology, Maryknoll Medical Center, Busan 48972, Korea, Republic of, ²Laboratory Medicine, Maryknoll Medical Center, Busan 48972, Korea, Republic of, ³Surgery, Maryknoll Medical Center, Busan 48972, Korea, Republic of, ⁴Urology, Maryknoll Medical Center, Busan 48972, Korea, Republic of, ⁵Pathology, Maryknoll Medical Center, Busan 48972, Korea, Republic of, ⁶Transplantation Center, Coordinator : Nurse, Maryknoll Medical Center, Busan 48972, Korea, Republic of
*Purpose: Purpose of our study is to evaluate the clinical significance of HLA class II epitope mismatch loads for the development of de novo DSA…